Acadia Pharmaceuticals | ACAD - Umsatzkosten





Umsatzkosten Veränderung Datum
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
ALKERMES USD 120.7M 47.44M 2026-06
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Biogen USD 945.1M 147.6M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Cara Therapeutics USD 0 0 2025-03
Corcept Therapeutics USD 4.06M 1.18M 2026-06
Cytokinetics USD 5.59M 5.43M 2026-06
Eisai JPY 51.09B 926M 2026-06
Eli Lilly USD 3.27B 309M 2026-06
Incyte USD 104.96M 457K 2026-06
J&J USD 8B 67M 2026-06
Moderna USD 93M 862M 2026-06
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Pfizer USD 4.09B 498M 2026-06
Prothena USD 28.94M 11.58M 2025-09
PTC Therapeutics USD 39.61M 23.31M 2026-03
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06